Figure 5
Sorafenib in combination with vitamin K1 (VK1) modulates the expression of Bcl-2 protein family in BT325 (A) and U251 (B) cells. The combination of the both agents exhibited strong synergistic action by inhibiting expression of Bcl-2 and Mcl-1 proteins, but showed little effects on expression of Bcl-xl and Bax proteins. Cells were treated with sorafenib (2.5 μM), VK1 (50 μM), or their combination for 24 h and β-actin was used as an internal control.